A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Clinical trial NCT05704634 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05704634
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-18
- Primary completion
- 2028-01-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.